Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

  • ID: 4410078
  • Report
  • 145 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Clovis Oncology Inc
  • Hager Biosciences LLC
  • IMPACT Therapeutics Inc
  • MORE
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

Summary

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 5, 9, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Fallopian Tube Cancer, Metastatic Breast Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Gastric Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Metastatic Pancreatic Cancer, Bile Duct Cancer (Cholangiocarcinoma), Glioblastoma Multiforme (GBM), Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, B-Cell Chronic Lymphocytic Leukemia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Esophageal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Laryngeal Cancer, Leiomyosarcoma, Liver Cancer, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Testicular Cancer, Traumatic Brain Injury, Unspecified and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Clovis Oncology Inc
  • Hager Biosciences LLC
  • IMPACT Therapeutics Inc
  • MORE
Introduction

REPORT COVERAGE

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development

AbbVie Inc

American Gene Technologies International Inc

AstraZeneca Plc

BeiGene Ltd

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Hager Biosciences LLC

Ildong Pharmaceutical Co Ltd

IMPACT Therapeutics Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Mitsubishi Tanabe Pharma Corp

Nerviano Medical Sciences Srl

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tasly Pharmaceutical Group Co Ltd

Tesaro Inc

Teva Pharmaceutical Industries Ltd

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles

2X-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABT-767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-0108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1775 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-6738 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGBA-317 + BGB-290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cediranib maleate + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-4297 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPI-289 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-124 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niraparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-293 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rucaparib camsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-10914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-3162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PARP1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOMCL-9112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSL-1502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZ-120312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YHP-743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones

Featured News & Press Releases

Sep 21, 2017: First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement

Sep 15, 2017: TESARO Receives Positive CHMP Opinion for ZEJULA

Sep 13, 2017: Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet

Sep 11, 2017: TESARO Summarizes ZEJULA Data Presented at 2017 ESMO Annual Meeting

Sep 08, 2017: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress

Sep 07, 2017: Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017

Aug 30, 2017: Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress

Aug 30, 2017: BeiGene Announces Presentations on its PARP inhibitor BGB-290 at the European Society for Medical Oncology 2017 Congress

Aug 25, 2017: TESARO Announces Eight Poster Presentations on ZEJULA at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting

Aug 17, 2017: FDA approves olaparib tablets for maintenance treatment in ovarian cancer

Aug 09, 2017: 2X Oncology Announces Validation of Drug Response Predictor for its PARP Inhibitor 2X-121

Aug 01, 2017: Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from Eisai

Jul 24, 2017: STA Signs Supply Agreement with TESARO

Jun 19, 2017: Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial

Jun 05, 2017: BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AbbVie Inc, H2 2017

Pipeline by American Gene Technologies International Inc, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by BeiGene Ltd, H2 2017

Pipeline by Checkpoint Therapeutics Inc, H2 2017

Pipeline by Clovis Oncology Inc, H2 2017

Pipeline by Hager Biosciences LLC, H2 2017

Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017

Pipeline by IMPACT Therapeutics Inc, H2 2017

Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017

Pipeline by Nerviano Medical Sciences Srl, H2 2017

Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H2 2017

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017

Pipeline by Tesaro Inc, H2 2017

Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • American Gene Technologies International Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Checkpoint Therapeutics Inc
  • Clovis Oncology Inc
  • Hager Biosciences LLC
  • Ildong Pharmaceutical Co Ltd
  • IMPACT Therapeutics Inc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Nerviano Medical Sciences Srl
  • Shanghai Acebright Pharmaceuticals Group Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • Tesaro Inc
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll